Disease oriented network
CZECRIN | ATMP
A disease oriented network linking clinical and research sites focused on research and development of Advanced Therapy Medicinal Products (ATMPs), including cellular, gene and tissue-based medicines.
The aim of the network is to support academic clinical research focused on the development, evaluation and implementation of ATMPs that bring new treatment options and therapeutic approaches not only for serious, rare and cancer diseases for which standard treatment options are not available or not effective enough.
The network contributes to the development of innovative medicines for modern therapies in the Czech Republic and supports their effective transfer from research and production laboratories to clinical practice.
Mission CZECRIN | ATMP
The mission of the CZECRIN | ATMP network is to support academic research and clinical trials of drugs for advanced therapies that can significantly expand the available therapeutic options for patients with cancer, serious or rare diseases for which standard therapeutic options are unavailable or insufficiently effective. The network creates an environment that brings together the expertise of clinical teams, research laboratories and manufacturing capabilities so that new scientific knowledge can be effectively translated into clinical practice and turned into real benefits for patients.
Vision CZECRIN | ATMP
- Build a national platform for clinical research on advanced therapies and ATMPs.
- To link cutting-edge clinical sites with research institutions and technology units to foster innovation in medicine.
- To support the design, validation and implementation of clinical trials in the field of ATMP with emphasis on safety, data quality and patient benefit.
- Strengthen international cooperation and active involvement of Czech research teams in international projects, including Horizon Europe programmes and European research initiatives focused on advanced therapies.
- Establish partnerships with foreign academic centres, manufacturing facilities and regulatory institutions that share know-how in the development, validation and clinical evaluation of ATMPs.
- To enable Czech patients to access state-of-the-art therapeutic approaches through academically initiated studies.
CZECRIN | ATMP is a disease oriented network
linking clinical and research sites in the field of advanced therapy medicinal products, known as Advanced Therapy Medicinal Products (ATMP). The network supports the establishment, implementation and development of academic clinical research on ATMP with the aim of contributing to innovation in the treatment of challenging diseases and improving the quality of care for patients with serious, rare and oncological diseases in the Czech Republic.
ATMPs include advanced therapeutic approaches such as gene therapy, cell therapy and tissue-engineered drugs that have the potential to treat diseases that are still difficult to treat with standard methods (e.g. in oncology, rare diseases or regenerative medicine).
Network target: Through coordinated research, education and sharing of expertise, CZECRIN | ATMP contributes to the development of advanced therapies and their effective implementation in clinical practice in the Czech Republic.
ATMPs involve innovative therapeutic approaches that use gene, cell and tissue technologies to treat diseases that have not yet been effectively addressed. These therapies allow for a personalised approach, are often developed in academic or hospital settings, and primarily target rare, genetic and cancer diseases.
Follow us on the networks!
